The bleeding risk in antithrombotic therapies: a narrative review.

The bleeding risk in antithrombotic therapies: a narrative review.
Curr Vasc Pharmacol. 2019 Feb 11;:
Authors: Alatri A, Mazzolai L
Abstract
Bleeding represents the most important complication of antithrombotic treatment, including anticoagulant and antiplatelet therapies. A number of scores were proposed to evaluate the risk of bleeding both for anticoagulant and antiplatelet treatment. In the last decade, 5 bleeding risk scores were published for use in atrial fibrillation patients, and 3 scores for patients receiving anticoagulants for venous thromboembolism therapy or prophylaxis. In addition, 3 scores were recently developed to assess in-hospital or short-term bleeding risk in patients receiving antiplatelet therapy after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Furthermore, 3 additional scores have focused on long-term bleeding in outpatients receiving dual antiplatelet therapy after PCI. The aim of this review is to consider the evidence on bleeding scores.
PMID: 30747072 [PubMed - as supplied by publisher]

Source: Current Vascular Pharmacology - February 11, 2019 Category: Drugs & Pharmacology Authors: Alatri A, Mazzolai L Tags: Curr Vasc Pharmacol Source Type: research